Venous ThromboembolismNCT01598805
Increased Rate of Prophylaxis Against Venous Thromboembolism Due to eAlerts
A study testing electronic alerts in people with Venous Thromboembolism, run by University of Zurich at 1 site in Switzerland.
Trial summary
Now, after a cluster randomized controlled trial, eAlerts providing evidence-based guidelines on venous thromboembolism prophylaxis will be rolled out and evaluated hospital-widely. Read more about this study
- Who is it for?
- Ages 16 years and older
- Conditions the study is for
- Venous Thromboembolism
- What is being tested?
- electronic alerts
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10,000 participants
- Where
- 1 siteSwitzerland
- Study dates
- Jun 2012to Sep 2012
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- all in-patients hospitalized in a ward with computerized physician order entry (CPOE),
- staying at least 24 h in a ward
Who cannot join
- outpatients,
- ward without CPOE,
- patients transferred from an intervention to a control ward and vice versa
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
University Hospital Zurich, Center for Clinical Research
Zurich
About this study
Now, after a cluster randomized controlled trial, eAlerts providing evidence-based guidelines on venous thromboembolism prophylaxis will be rolled out and evaluated hospital-widely.
Read the detailed description
An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer. The eAlerts provide evidence-based guidelines on venous thromboembolism prophylaxis. Now, after a cluster randomized controlled trial, the eAlerts will be rolled out and evaluated hospital-widely.
- Conditions
- Venous Thromboembolism
- Being tested
- electronic alerts
- Keywords
- venous thromboembolism/prevention & control
- Medical subject headings
- Venous Thromboembolism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
electronic alertsBehavioural
Also called eAlert
An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer.
| Study group | Role | What they receive |
|---|---|---|
| roll out of eAlerts | Experimental | Roll out of eAlerts providing evidence-based guidelines on prophylaxis against venous thromboembolism. An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer. Receives: Behavioral: electronic alerts |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rate of prophylaxis against venous thromboembolism
patients with prophylaxis/total patients
Measured: 3 months
Secondary outcomes (2)
ordering time after admission or transfer of a patient
time when physicians order a venous thromboembolism prophylaxis
Measured: 3 months
acceptance of the eAlerts
survey of compliant and incompliant physicians
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 May 2012 (estimated)
- Study startJun 2012
- Primary completionSep 2012
- Study completionSep 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Venous ThromboembolismStudies of the same condition, open and under way.
- More trials run by University of ZurichThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 10,000 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Zurich
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Juerg Blaser, Prof. PhD, Principal investigator, University Hospital Zurich, Center for Clinical Research, Research Center for Medical Informatics
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01598805
- Sponsor's protocol ID
- FZMI-KEK-ZH-Nr. 2010-0458
- Status last verified
- Nov 2012
- First submitted
- 11 May 2012
- Last updated
- 16 Nov 2012
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Nov 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Increased Rate of Prophylaxis Against Venous Thromboembolism Due to eAlerts
- ClinicalTrials.gov ID
- NCT01598805
- Acronym / sponsor ID
- FZMI-KEK-ZH-Nr. 2010-0458
- Conditions
- Venous Thromboembolism
- Keywords
- venous thromboembolism/prevention & control
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 10,000 participants (actual)
- Lead sponsor
- University of ZurichUniversity, hospital or other
- Study start
- Jun 2012
- Primary completion
- Sep 2012 (actual)
- Study completion
- Sep 2012 (actual)
- First posted
- 15 May 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Now, after a cluster randomized controlled trial, eAlerts providing evidence-based guidelines on venous thromboembolism prophylaxis will be rolled out and evaluated hospital-widely.
Detailed description
An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer. The eAlerts provide evidence-based guidelines on venous thromboembolism prophylaxis. Now, after a cluster randomized controlled trial, the eAlerts will be rolled out and evaluated hospital-widely.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- Single blind (participant)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| roll out of eAlerts | Experimental | Behavioral: electronic alertsRoll out of eAlerts providing evidence-based guidelines on prophylaxis against venous thromboembolism. An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer. |
Who may qualify
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (2 listed)
- all in-patients hospitalized in a ward with computerized physician order entry (CPOE),
- staying at least 24 h in a ward
Key exclusion criteria (3 listed)
- outpatients,
- ward without CPOE,
- patients transferred from an intervention to a control ward and vice versa
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| electronic alertsAlso: eAlertAn eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer. | Behavioural | roll out of eAlerts |
Primary outcome
Rate of prophylaxis against venous thromboembolism
Time frame: 3 months
patients with prophylaxis/total patients
2 secondary outcomes
ordering time after admission or transfer of a patient
Time frame: 3 months
acceptance of the eAlerts
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Nov 2012.
Related trials for Venous Thromboembolism
RecruitingPhase 3
REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults
Venous Thromboembolism (VTE)
RecruitingPhase 3
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
Venous Thromboembolism (VTE)
RecruitingPhase 3
REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
Cancer-Associated Thrombosis (CAT)
RecruitingPhase 3
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
Symptomatic Venous Thromboembolism (VTE)
Recruiting
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
Venous Thromboembolism, Deep Venous Thrombosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Juerg Blaser, Prof. PhD principal investigator
University Hospital Zurich, Center for Clinical Research, Research Center for Medical Informatics
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing electronic alerts in people with Venous Thromboembolism, run by University of Zurich at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Nov 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rate of prophylaxis against venous thromboembolism (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Nov 2012.